News | May 11, 2011

Scale Helps Keep Heart Failure Patients at Home

May 11, 2011 – Every day, Jack Luzovich steps on a special scale that helps keep him in his northern Minnesota home, rather than the hospital. At age 61, he is fighting the debilitating symptoms of congestive heart failure. Last summer, his health hit a low point. “I was retaining fluid and my weight was going up and down,” he remembers. “I couldn’t walk more than 10 to 15 feet. I was on oxygen, jaundiced and had almost no kidney function.”

That’s when Jack received a telemonitoring scale from the Essentia Health Heart Failure Program (formerly St. Mary’s Duluth Clinic Heart Failure Program). The device records his weight and asks him questions about his health. It transmits that vital information to a cardiac nurse, who can make changes to his medications and track his condition on a daily basis.

This program, which began more than a decade ago in Duluth, Minn., has posted dramatic results. While national hospital readmission rates for congestive heart failure patients at six months are 40 to 50 percent, Essentia’s sickest heart failure patients, who use the telescale, have readmission rates from 0 to 2 percent. Readmission rates for all patients in the program have hovered around 3 to 7 percent.

The cost benefit is also impressive. An Essentia Health study conducted in partnership with insurance company Blue Cross Blue Shield of Minnesota showed $1.25 million in savings for just 29 patients over six months. These statistics caught the attention of a federal program designed to quickly spread great healthcare ideas across the nation – the Health Care Innovations Exchange, part of the Agency for Healthcare Research and Quality (AHRQ). AHRQ invited Linda Wick, N.P., Heart Failure Program manager, to showcase this concept on Wednesday, May 11, before a panel representing investors, insurers, charitable foundations and healthcare consultants at the AHRQ Innovations Exchange in Rockville, Md.

The group discussed how this program’s success could be replicated at other institutions around the country. “The Innovations Exchange does a rigorous review of programs before deciding to share them nationwide,” Wick says.

Being recognized by the Health Care Innovations Exchange is one of the many ways Essentia Health is providing creative solutions to healthcare challenges, says Chief Medical Officer Carl Heltne, M.D. A cardiologist by training, Heltne founded the Heart Failure Program in 1998.

“Our vision for Essentia Health is to be a national leader in providing high quality, cost-effective integrated healthcare services, particularly in rural areas,” said Heltne. “This program improves quality of life while substantially reducing costs. It’s exactly the type of leadership we are talking about.”

Luzovich sees the value of the program for heart failure patients like him. A year after he began using the scale, his health is greatly improved. He’s back enjoying his favorite hobbies, like woodworking in his basement. “Now I’m running up and down stairs,” he said. “Before, it was up two steps and stop.”

Luzovich had a left ventricular assist device placed last summer, which keeps his heart pumping. As he waits on the heart transplant list, he continues to use his telescale and keeps in regular contact with his caregivers at Essentia Health.

“It’s been a lifesaver for my wife and me,” Luzovich said. “This keeps you from getting into really major trouble. The nurses in the program have become like family.”

For more information: essentiahealth.org

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Medical Metrics Taps Digisonics Cardiovascular Information Systems for Clinical Trials
News | Cardiac PACS| October 03, 2017
October 3, 2017 – Medical Metrics, an experienced core laboratory for multi-center clinical trials, has implemented t
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Overlay Init